公司资料
Editas Medicine 股价、新闻与催化剂
- 股票代码:
- EDIT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.84 USD (+0.71%)
收盘价
最后更新: 2026年8月17日
433M USD
市值
股价为何变动
As of Aug 17, 2026, EDIT closed up 0.71% at $2.84. No new same-company headline was identified in the current news window.
公司概览
In Vivo CRISPR Medicines
Editas Medicine is developing in vivo CRISPR gene-editing therapies intended to produce durable therapeutic effects after a single administration. Following the discontinuation of its earlier reni-cel program, the company’s near-term strategy is concentrated on cardiometabolic editing.
EDIT-401
EDIT-401 is designed to upregulate LDL receptor protein in the liver and thereby lower LDL cholesterol. Preclinical studies showed large mean LDL-C reductions and also demonstrated reductions in apolipoprotein B and lipoprotein(a), supporting its development as a one-time treatment for hyperlipidemia.
Initial HeFH Development
The first clinical indication is heterozygous familial hypercholesterolemia, an inherited disorder that produces elevated LDL-C and early cardiovascular risk. Editas plans to use the initial trial to establish safety, dose response and human proof of concept before considering broader hyperlipidemia populations.
未来催化剂
- Initiation of the first-in-human EDIT-401 trial in 2026.
- Early human proof-of-concept data for EDIT-401 expected by year-end 2026.
- Completion of dose-finding enrollment and topline EDIT-401 results expected in 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。